Danish drugmaker Novo Nordisk (NOV: N) has reported sales in line with expectations at 108 billion Danish kroner ($15.98 billion) for the first six months in 2023, up 30% from the same period a year earlier.
Earnings per share were 17.41 Danish kroner, up 44% but slightly below expectations.
Sales of semaglutide, the company’s glucagon-like peptide-1 receptor agonist, are a major reason for Novo Nordisk’s stellar performance, both under its Wegovy guise as a breakthrough obesity drug and as Ozempic to treat type 2 diabetes and prevent major cardiovascular problems.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze